The approval of selective RET inhibitors brings significant improvements to the treatment of aberrant RET positive patients, including non-small cell lung cancer and thyroid cancer. However, the drug resistance of these first-generation selective RET inhibitors was reported recently. Compared with EGFR, ALK and other targets, there are no drugs targeting RET resistant mutations, and patients usually have disease progression again after experiencing effective treatment. The reported drug resistance mechanism is the on target mutation represented by the RET G810R/S solvent frontier mutations, which hinders the binding of first-generation RET inhibitors to the target and finally results in drug resistance. APS03118, with unique structural advantages, can effectively inhibit RET solvent frontier mutations and displays remarkable anti-tumor effect in multiple mouse models with good tolerance.
Address
Office: San Diego,US
Office: Building 10-1, No.2 Jingyuan North Street, BDA, Beijing, China
Tel
+86-10-67860673